Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biogen to Evaluate GlycoFi's Protein Production Platform.


Health/Medical Writers

BIOWIRE2K

LEBANON, N.H. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2003

GlycoFi, Inc. and Biogen, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: BGEN BGen
abbr.
brigadier general
) announce the initiation of a joint research study to evaluate GlycoFi's Humanized yeast(TM) platform for the production of an undisclosed Biogen protein. The study, supported by Biogen, will combine GlycoFi's unique expression technology to produce human glycoproteins of unprecedented uniformity with Biogen's expertise in the area of therapeutic protein discovery and manufacturing.

About GlycoFi

GlycoFi, Inc. is the industry leader for the engineering and production of therapeutic glycoproteins in yeast systems. The company was founded in 2000 with the mission to be a leading biotechnology company in the development, manufacturing, and commercialization of biotherapeutics. The company has engineered yeast and other fungal fungal /fun·gal/ (fun´g'l) fungous; pertaining to fungi.

fun·gal or fun·gous
adj.
1. Of, relating to, resembling, or characteristic of a fungus.

2.
 protein expression systems to produce fully humanized glycoproteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information, please visit www.glycofi.com.

About Biogen

Biogen is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic , neurobiology Neurobiology

Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their
 and oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.

on·col·o·gy
n.
, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities. For press releases and additional information about the company, please visit www.biogen.com.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 10, 2003
Words:215
Previous Article:Register.com Reports Third Quarter 2003 Financial Results.
Next Article:Island Pacific Completes $4.9 Million Common Stock Private Placement.
Topics:



Related Articles
Studies on protein, fat to improve flavor, safety of fermented meats.
HIGHER DOSES OF INTERFERON BETA-1A GIVE NO ADDED BENEFIT.
NeoGenesis and Biogen, Inc. Expand Small Molecule Discovery Relationship; Companies Reach Agreement Based on Previous Success.
GlycoFi Appoints Margaret Worden to Vice President of Clinical Product Development.
XENCOR LICENSES CHRONOS' ACE TO GENERATE PDA CELL LINES.
Biogen Idec to Expand Oncology Pipeline with Acquisition of Conforma Therapeutics.
Merck announces it has agreed to purchase two biotechnology firms that will help it discover and produce products.
Biogen Idec Researchers Identify Potential New Pathway in Rheumatoid Arthritis Disease Process.
A new treatment option: Tysabri returns, with controls.
FDA postpones Tysabri decision.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles